Company news
Lunai Bioworks Inc. news in 2025
Lunai Bioworks Inc.'s news releases, calls and decks from 2025, newest first.
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
December 9, 2025
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models
November 24, 2025
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
November 4, 2025
Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds
October 30, 2025
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 15, 2025
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline
October 5, 2025
Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense
September 29, 2025
Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships
September 24, 2025
Lunai Bioworks, Inc. to Effect 10: 1 Reverse Stock Split
September 23, 2025
Lunai Bioworks Strengthens European Strategy Through Restructuring
September 7, 2025